Innovent Biologics
Innovent Biologics, also known as Innovent, is a leading biopharmaceutical company headquartered in China (CN). Founded in 2011, the company has rapidly established itself in the biopharmaceutical industry, focusing on the development, manufacturing, and commercialisation of innovative therapies for oncology, autoimmune diseases, and other serious conditions. With a strong presence in major operational regions across Asia and beyond, Innovent is recognised for its robust pipeline of monoclonal antibodies and biosimilars. Their flagship products, including the PD-1 inhibitor Tyvyt, have garnered significant attention for their unique mechanisms of action and efficacy. Innovent's commitment to research and development has positioned it as a key player in the global market, achieving notable milestones such as successful partnerships and regulatory approvals that underscore its reputation for excellence in biopharmaceutical innovation.
DitchCarbon Score
How does Innovent Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innovent Biologics's score of 33 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Innovent Biologics's reported carbon emissions
In 2023, Innovent Biologics reported total carbon emissions of approximately 15,894,420 kg CO2e. This figure includes 65,170 kg CO2e from Scope 1 emissions and about 15,829,250 kg CO2e from Scope 2 emissions. Notably, their Scope 3 emissions, which encompass purchased goods and services, also totalled approximately 15,894,420 kg CO2e. Comparatively, in 2022, the company recorded total emissions of about 22,302,950 kg CO2e, with Scope 1 emissions at 66,740 kg CO2e and Scope 2 emissions at approximately 22,236,210 kg CO2e. This indicates a significant reduction in total emissions from 2022 to 2023. Despite these reductions, Innovent Biologics has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of defined reduction strategies suggests a need for further commitment to climate action within the biopharmaceutical industry context.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 39,400 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 39,400 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Innovent Biologics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
